Athenex, Inc. (ATNX): Price and Financial Metrics


Athenex, Inc. (ATNX)

Today's Latest Price: $12.39 USD

0.58 (4.91%)

Updated Sep 25 4:00pm

Add ATNX to Watchlist
Sign Up

Overall POWR Rating


POWR Components:

 Trade Grade  Buy & Hold Grade  Peer Grade  Industry Rank


Industry Rank:

Ranked of 233 in Medical - Pharmaceuticals

See all "A" rated Strong Buy stocks

ATNX Stock Summary

  • ATNX's went public 3.29 years ago, making it older than just 10.86% of listed US stocks we're tracking.
  • With a year-over-year growth in debt of 71.81%, Athenex Inc's debt growth rate surpasses 84.45% of about US stocks.
  • As for revenue growth, note that ATNX's revenue has grown 61.5% over the past 12 months; that beats the revenue growth of 91.74% of US companies in our set.
  • Stocks that are quantitatively similar to ATNX, based on their financial statements, market capitalization, and price volatility, are RTRX, PFNX, BLDP, UTSI, and KMDA.
  • Visit ATNX's SEC page to see the company's official filings. To visit the company's web site, go to www.athenex.com.
ATNX Daily Price Range
ATNX 52-Week Price Range

ATNX Stock Price Chart Technical Analysis Charts


ATNX Price/Volume Stats

Current price $12.39 52-week high $18.35
Prev. close $11.81 52-week low $5.63
Day low $12.00 Volume 716,412
Day high $12.48 Avg. volume 704,140
50-day MA $11.80 Dividend yield N/A
200-day MA $11.93 Market Cap 1.01B

Athenex, Inc. (ATNX) Company Bio


Athenex Inc. is a global biopharmaceutical company dedicated to the discovery, development and commercialization of novel therapies for the treatment of cancer. The company was founded in 2003 and is based in Buffalo, New York.


ATNX Latest News Stream


Event/Time News Detail
Loading, please wait...

ATNX Latest Social Stream


Loading social stream, please wait...

View Full ATNX Social Stream

Latest ATNX News From Around the Web

Below are the latest news stories about Athenex Inc that investors may wish to consider to help them evaluate ATNX as an investment opportunity.

Athenex Announces FDA Allowance of IND Application for TCRT-ESO-A2, a TCR-T Cell Therapy

Athenex’s first T cell therapy product cleared to advance to the first stage of clinical development in the U.S.BUFFALO, N.Y., Sept. 23, 2020 (GLOBE NEWSWIRE) -- Athenex, Inc. (NASDAQ: ATNX), a global biopharmaceutical company dedicated to the discovery, development and commercialization of novel therapies for the treatment of cancer and related conditions, today announced that the U.S. Food and Drug Administration (FDA) has allowed its Investigational New Drug (IND) application for TCRT-ESO-A2, an autologous T cell receptor (TCR)-T cell therapy targeting solid tumors that are NY-ESO-1 positive in HLA-A*02:01 positive patients. TCRT-ESO-A2 is being developed by Axis Therapeutics Limited, a joint venture between Athenex and Xiangxue Life Sciences Limited (“XLifeSc"), a subsidiary o...

Yahoo | September 23, 2020

A Biotech Pro Bought Up These 3 Stocks

Perceptive Advisors and its hedge fund recently invested a total of $60 million in Athenex, Albireo, and Quotient stock. Two of the stocks are slumping in 2020.

Yahoo | September 19, 2020

Athenex (ATNX) Investor Presentation - Slideshow

The following slide deck was published by Athenex, Inc. in conjunction with this event....

SA Transcripts on Seeking Alpha | September 11, 2020

Why Athenex Stock Is Down Today

Shares of Athenex (NASDAQ: ATNX) were down by 14.3% as of 1:35 p.m. EDT on Thursday, following the company's announcement of the pricing of a public offering of common stock. With Athenex set to dilute existing shareholders, it isn't surprising that investors are selling off shares of the biotech today. Athenex first announced its intention to raise funds through a public offering on Tuesday.

Yahoo | September 10, 2020

Athenex, Inc. Announces Pricing of $110 Million Public Offering of Common Stock

BUFFALO, N.Y., Sept. 10, 2020 (GLOBE NEWSWIRE) -- Athenex, Inc. (Nasdaq: ATNX), a global biopharmaceutical company dedicated to the discovery, development and commercialization of novel therapies for the treatment of cancer, today announced the pricing of a public offering of 10,000,000 shares of its common stock at a public offering price of $11.00 per share. The gross proceeds to Athenex from the offering, before underwriting discounts and commissions and estimated offering expenses, are expected to be $110 million. In addition, Athenex has granted the underwriters a 30-day option to purchase up to an additional 1,500,000 shares of common stock at the public offering price, less underwriting discounts and commissions. The offering is expected to close on September 14, 2020, subject to...

Yahoo | September 10, 2020

Read More 'ATNX' Stories Here

ATNX Price Returns

1-mo 15.69%
3-mo -7.47%
6-mo 60.08%
1-year -1.47%
3-year -27.50%
5-year N/A
YTD -18.86%
2019 20.33%
2018 -20.19%
2017 N/A
2016 N/A
2015 N/A

Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com!



Page generated in 0.8229 seconds.